JP2020512361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512361A5 JP2020512361A5 JP2019553224A JP2019553224A JP2020512361A5 JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5 JP 2019553224 A JP2019553224 A JP 2019553224A JP 2019553224 A JP2019553224 A JP 2019553224A JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- complex
- molecule
- combination
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003812 Interleukin-15 Human genes 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 7
- 239000000539 dimer Substances 0.000 claims description 6
- 210000000822 natural killer cell Anatomy 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000012526 B-cell neoplasm Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010028811 Natural killer-cell leukaemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 229940125716 antipyretic agent Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229960002204 daratumumab Drugs 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 229950007752 isatuximab Drugs 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 2
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108010057840 ALT-803 Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 2
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480339P | 2017-03-31 | 2017-03-31 | |
| US62/480,339 | 2017-03-31 | ||
| US15/937,493 | 2018-03-27 | ||
| US15/937,493 US20190048055A1 (en) | 2017-03-31 | 2018-03-27 | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
| PCT/US2018/025366 WO2018183821A1 (en) | 2017-03-31 | 2018-03-30 | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512361A JP2020512361A (ja) | 2020-04-23 |
| JP2020512361A5 true JP2020512361A5 (enExample) | 2021-04-30 |
Family
ID=63678335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553224A Pending JP2020512361A (ja) | 2017-03-31 | 2018-03-30 | 癌治療のために抗ｃｄ３８抗体と併用したａｌｔ−８０３ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190048055A1 (enExample) |
| EP (1) | EP3601363B1 (enExample) |
| JP (1) | JP2020512361A (enExample) |
| KR (1) | KR102748188B1 (enExample) |
| CN (1) | CN110494449B (enExample) |
| AU (1) | AU2018243550B2 (enExample) |
| CA (1) | CA3058427C (enExample) |
| TW (1) | TW201841651A (enExample) |
| WO (1) | WO2018183821A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109496217B (zh) | 2016-05-27 | 2023-10-20 | 阿尔托生物科学有限公司 | 具有cd3结合域的基于多聚体il-15的分子的构造和表征 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3055318C (en) | 2017-03-06 | 2025-11-25 | Altor Bioscience Corp | Il-15-based fusions to il-12 and il-18 |
| CN114787181A (zh) * | 2019-11-21 | 2022-07-22 | Inserm(法国国家健康医学研究院) | 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法 |
| KR102692667B1 (ko) | 2020-11-17 | 2024-08-06 | 고려대학교 산학협력단 | 면역치료요법의 효능, 예후, 또는 내성 예측을 위한 바이오마커, 및 면역치료요법의 효능 증진을 위한 표적으로서 tctp의 용도 |
| CN113293191A (zh) * | 2021-05-28 | 2021-08-24 | 山东大学齐鲁医院 | Gfp转染肿瘤细胞的方法在检测肿瘤相关巨噬细胞吞噬功能中的应用 |
| WO2023178253A2 (en) * | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
| GB202315149D0 (en) | 2023-10-03 | 2023-11-15 | Celleron Therapeutics Ltd | Combination therapy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US222A (en) | 1837-06-10 | Truss for the retention and radical cure qe hernia | ||
| US8507A (en) | 1851-11-11 | petess | ||
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1994004689A1 (en) | 1992-08-14 | 1994-03-03 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7213961B2 (en) | 2003-07-11 | 2007-05-08 | Hubbell Incorporated | Low voltage luminaire assembly |
| US8772451B2 (en) | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| EA015584B1 (ru) * | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| CN105017429B (zh) * | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| ES2747997T3 (es) * | 2012-10-24 | 2020-03-12 | Novartis Ag | Formas de IL-15R alfa, células que expresan formas de IL-15R alfa, y usos terapéuticos de IL-15R alfa y complejos IL-15/IL-15R alfa |
| EP3160498B1 (en) * | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| MX389663B (es) * | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| EP3359157A4 (en) * | 2015-10-06 | 2019-05-15 | The Wistar Institute Of Anatomy And Biology | METHOD AND COMPOSITIONS FOR THE TREATMENT OF METASTASIVE AND REFRACTORY CANCER DISEASES AND TUMORS |
-
2018
- 2018-03-27 US US15/937,493 patent/US20190048055A1/en not_active Abandoned
- 2018-03-30 AU AU2018243550A patent/AU2018243550B2/en active Active
- 2018-03-30 CA CA3058427A patent/CA3058427C/en active Active
- 2018-03-30 CN CN201880022531.7A patent/CN110494449B/zh active Active
- 2018-03-30 KR KR1020197032255A patent/KR102748188B1/ko active Active
- 2018-03-30 WO PCT/US2018/025366 patent/WO2018183821A1/en not_active Ceased
- 2018-03-30 EP EP18776459.2A patent/EP3601363B1/en active Active
- 2018-03-30 JP JP2019553224A patent/JP2020512361A/ja active Pending
- 2018-03-31 TW TW107111499A patent/TW201841651A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512361A5 (enExample) | ||
| EP2944323B1 (en) | Agents for treating tumours, use and method thereof | |
| JP2019515888A5 (enExample) | ||
| JP2019516748A5 (enExample) | ||
| Luedke et al. | Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| JP2014525925A (ja) | 抗−ｃｄ１９抗体とプリン類似体の併用治療 | |
| JP2015517511A5 (enExample) | ||
| US20200377596A1 (en) | Dosing of bispecific t cell engager | |
| EP3972609B1 (en) | Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release | |
| JP2020510011A5 (enExample) | ||
| JPWO2020043683A5 (enExample) | ||
| JP2022130602A (ja) | 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用 | |
| CN102935228B (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| AU2022253906A1 (en) | Dosing of bispecific t cell engager | |
| JP2013543869A5 (enExample) | ||
| JP2016104703A (ja) | 抗腫瘍剤 | |
| US9687472B2 (en) | Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress | |
| Zhang et al. | PF299 EARLY RESPONSE OBSERVATION OF PEDIATRIC PATIENTS WITH BURKITT'S LYMPHOMA TREATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS | |
| Zent | Monoclonal antibody therapy in chronic lymphocytic leukemia | |
| Maria-Ferreira et al. | OPEN ACCESS EDITED BY | |
| TW202517679A (zh) | 以抗ｉｌｔ２抗體治療癌症 | |
| JPWO2021108926A5 (enExample) | ||
| Karatrasoglou et al. | Oncology news/literature Review/July-December 2019 | |
| Wendtner | Combination treatment for metastatic breast cancer |